These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

567 related articles for article (PubMed ID: 30053126)

  • 21. Genomics and proteomics to determine novel molecular subtypes and predict the response to immunotherapy and the effect of bevacizumab in glioblastoma.
    Luo D; Luo A; Hu S; Ye G; Li D; Zhao H; Peng B
    Sci Rep; 2024 Jul; 14(1):17630. PubMed ID: 39085480
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined expressional analysis, bioinformatics and targeted proteomics identify new potential therapeutic targets in glioblastoma stem cells.
    Stangeland B; Mughal AA; Grieg Z; Sandberg CJ; Joel M; Nygård S; Meling T; Murrell W; Vik Mo EO; Langmoen IA
    Oncotarget; 2015 Sep; 6(28):26192-215. PubMed ID: 26295306
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of intrinsic subtype-specific prognostic microRNAs in primary glioblastoma.
    Li R; Gao K; Luo H; Wang X; Shi Y; Dong Q; Luan W; You Y
    J Exp Clin Cancer Res; 2014 Jan; 33(1):9. PubMed ID: 24438238
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Silencing LncRNA LOXL1-AS1 attenuates mesenchymal characteristics of glioblastoma via NF-κB pathway.
    Wang H; Li L; Yin L
    Biochem Biophys Res Commun; 2018 Jun; 500(2):518-524. PubMed ID: 29678575
    [TBL] [Abstract][Full Text] [Related]  

  • 25. An immunoevasive strategy through clinically-relevant pan-cancer genomic and transcriptomic alterations of JAK-STAT signaling components.
    Chang WH; Lai AG
    Mol Med; 2019 Nov; 25(1):46. PubMed ID: 31684858
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic estimates of aneuploid content in glioblastoma multiforme and improved classification.
    Li B; Senbabaoglu Y; Peng W; Yang ML; Xu J; Li JZ
    Clin Cancer Res; 2012 Oct; 18(20):5595-605. PubMed ID: 22912392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy.
    Carrato C; Alameda F; Esteve-Codina A; Pineda E; Arpí O; Martinez-García M; Mallo M; Gut M; Lopez-Martos R; Barco SD; Ribalta T; Capellades J; Puig J; Gallego O; Mesia C; Muñoz-Marmol AM; Archilla I; Arumí M; Blanc JM; Bellosillo B; Menendez S; Esteve A; Bagué S; Hernandez A; Craven-Bartle J; Fuentes R; Vidal N; Aldecoa I; Iglesia N; Balana C
    Clin Cancer Res; 2020 Dec; 26(24):6600-6609. PubMed ID: 32998960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas.
    Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X
    Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
    Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
    Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peroxisome proliferator-activated receptor gamma as a theragnostic target for mesenchymal-type glioblastoma patients.
    Hua TNM; Oh J; Kim S; Antonio JM; Vo VTA; Om J; Choi JW; Kim JY; Jung CW; Park MJ; Jeong Y
    Exp Mol Med; 2020 Apr; 52(4):629-642. PubMed ID: 32280134
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response.
    Nickerson ML; Witte N; Im KM; Turan S; Owens C; Misner K; Tsang SX; Cai Z; Wu S; Dean M; Costello JC; Theodorescu D
    Oncogene; 2017 Jan; 36(1):35-46. PubMed ID: 27270441
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transcriptome analyses reveal molecular mechanisms underlying phenotypic differences among transcriptional subtypes of glioblastoma.
    Pan YB; Wang S; Yang B; Jiang Z; Lenahan C; Wang J; Zhang J; Shao A
    J Cell Mol Med; 2020 Apr; 24(7):3901-3916. PubMed ID: 32091665
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Spatial transcriptome analysis reveals Notch pathway-associated prognostic markers in IDH1 wild-type glioblastoma involving the subventricular zone.
    Jungk C; Mock A; Exner J; Geisenberger C; Warta R; Capper D; Abdollahi A; Friauf S; Lahrmann B; Grabe N; Beckhove P; von Deimling A; Unterberg A; Herold-Mende C
    BMC Med; 2016 Oct; 14(1):170. PubMed ID: 27782828
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bioinformatics analyses of significant genes, related pathways and candidate prognostic biomarkers in glioblastoma.
    Zhou L; Tang H; Wang F; Chen L; Ou S; Wu T; Xu J; Guo K
    Mol Med Rep; 2018 Nov; 18(5):4185-4196. PubMed ID: 30132538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of HOXC10 promotes glioblastoma cell progression to a poor prognosis via the PI3K/AKT signalling pathway.
    Guan Y; He Y; Lv S; Hou X; Li L; Song J
    J Drug Target; 2019 Jan; 27(1):60-66. PubMed ID: 29768063
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development and validation of prognostic markers in sarcomas base on a multi-omics analysis.
    Song Y; Yang K; Sun T; Tang R
    BMC Med Genomics; 2021 Jan; 14(1):31. PubMed ID: 33509178
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An integrative pan-cancer investigation reveals common genetic and transcriptional alterations of AMPK pathway genes as important predictors of clinical outcomes across major cancer types.
    Chang WH; Lai AG
    BMC Cancer; 2020 Aug; 20(1):773. PubMed ID: 32807122
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics.
    Li R; Chen X; You Y; Wang X; Liu Y; Hu Q; Yan W
    Oncotarget; 2015 Oct; 6(31):30968-74. PubMed ID: 26427041
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models.
    Spoerke JM; O'Brien C; Huw L; Koeppen H; Fridlyand J; Brachmann RK; Haverty PM; Pandita A; Mohan S; Sampath D; Friedman LS; Ross L; Hampton GM; Amler LC; Shames DS; Lackner MR
    Clin Cancer Res; 2012 Dec; 18(24):6771-83. PubMed ID: 23136191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nuclear factor I A promotes temozolomide resistance in glioblastoma via activation of nuclear factor κB pathway.
    Yu X; Wang M; Zuo J; Wahafu A; Mao P; Li R; Wu W; Xie W; Wang J
    Life Sci; 2019 Nov; 236():116917. PubMed ID: 31614149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.